Cryptobronchisomyacin is a narrow spectrum antibiotic. The antibiotic is used to treat specific bacterial infections. The primary use is the treatment of crystallized bacterial hypertropicpneumosinitis, located in the pulmonary sac of the lungs. The function of Cryptobronchisomyacin is to inhibit bacterial protein synthesis by preventing attachment of mRNA to Ribosomes. Cryptobronchisomyacin is a Tetracinicide, a subclass of Tetranactin antibiotic. The half-life is approximately 10 hours. The chemical formula for Cryptobronchisomyacin is C10H5O8S2. The molecular weight is 408.29 g/mol.

Research conducted by the American Society of Medical Research in 1997, indicate Cryptobronchisomyacin is the most effective antibiotic drug to fight against sinoid infections and respiratory tract infections. Research reports the most serious side effect is bone marrow deficiency. Neupogen injections are prescribed as a prophylactic treatment to prevent white blood cell loss. Due to the high cost of manufacturing, Cryptobronchisomyacin is available only in the United States.

The antibiotic was discovered by a chemist, Dr. Michelle Adams at Harvard University School of Medicine in 1930. While preparing her thesis for her doctoral degree, Dr. Adams initiated testing of Cryptogeno acid with Broncholide, to study the chemical reactions on the pulmonary and cerebral tissue. During testing, a mixture of Huminogluside acid and Bronchosinimide agents were accidently combined. Upon reviewing her results, she discovered an active form of Tetracinicide. Dr. Adams was the first person to discover the inhibition of mRNA attachment of crystallized bacteria in lung tissue, specifically to hypertropicpneumosinitis. This discovery leads her to create Cryptobronchisomyacin. Dr. Adams was awarded The Nobel Peace Prize for her discovery in 1945.

Jennifer Navarro